{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T18:22:56Z","timestamp":1777141376088,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunosuppressive therapy can decrease rejection episodes and increase the risk of severe and fatal infections in heart transplantation (HT) recipients. Immunosuppressive therapy can also decrease the absolute lymphocyte count (ALC), but the relationship between early post-transplant ALC and early cytomegalovirus (CMV) infection is largely unknown, especially in HT. We retrospectively analyzed 58 HT recipients who tested positive for CMV IgG antibody and received basiliximab induction therapy. We collected preoperative and 2-month postoperative data on ALC and CMV load. The CMV load\u2009&gt;\u20091200\u00a0IU\/mL was used as the cutoff value to define early CMV infection. Post-transplant lymphopenia was defined as an ALC of\u2009&lt;\u2009500 cells\/\u03bcL at postoperative day (POD) #7. On POD #7, 29 (50.0%) patients had post-transplant lymphopenia and 29 (50.0%) patients did not. The incidence of CMV infection within 1 or 2\u00a0months of HT was higher in the post-transplant lymphopenia group than in the non-lymphopenia group (82.8% vs. 48.3%, <jats:italic>P<\/jats:italic>\u2009=\u20090.013; 89.7% vs. 65.5%, <jats:italic>P<\/jats:italic>\u2009=\u20090.028, respectively). ALC\u2009&lt;\u2009500 cells\/\u03bcL on POD #7 was an independent risk factor for early CMV infection within 1\u00a0month of HT (odds ratio, 4.14; 95% confidence interval, 1.16\u201314.77; <jats:italic>P<\/jats:italic>\u2009=\u20090.029). A low ALC after HT was associated with a high risk of early CMV infection. Post-transplant ALC monitoring is simple and inexpensive and can help identify patients at high risk of early CMV infection.<\/jats:p>","DOI":"10.1038\/s41598-020-80790-4","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:11:08Z","timestamp":1610622668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Post-transplant absolute lymphocyte count predicts early cytomegalovirus infection after heart transplantation"],"prefix":"10.1038","volume":"11","author":[{"given":"Minjae","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaewon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeong-Hyeon","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"80790_CR1","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.transproceed.2012.09.035","volume":"44","author":"E Mendez-Eirin","year":"2012","unstructured":"Mendez-Eirin, E. et al. Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: Effect of preemptive therapy. Transpl. Proc. 44, 2660\u20132662 (2012).","journal-title":"Transpl. Proc."},{"key":"80790_CR2","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1093\/ajhp\/62.suppl_1.S7","volume":"62","author":"RR Razonable","year":"2005","unstructured":"Razonable, R. R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am. J. Health Syst. Pharm. 62, S7-13 (2005).","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"Suppl 7","key":"80790_CR3","doi-asserted-by":"publisher","first-page":"S754","DOI":"10.1093\/clinids\/12.Supplement_7.S754","volume":"12","author":"RH Rubin","year":"1990","unstructured":"Rubin, R. H. Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12(Suppl 7), S754-766 (1990).","journal-title":"Rev. Infect. Dis."},{"key":"80790_CR4","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/0003-4819-143-12-200512200-00005","volume":"143","author":"AC Kalil","year":"2005","unstructured":"Kalil, A. C., Levitsky, J., Lyden, E., Stoner, J. & Freifeld, A. G. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med. 143, 870\u2013880 (2005).","journal-title":"Ann. Intern. Med."},{"key":"80790_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton, C. N. et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102, 900\u2013931 (2018).","journal-title":"Transplantation"},{"key":"80790_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","volume":"29","author":"MR Costanzo","year":"2010","unstructured":"Costanzo, M. R. et al. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J. Heart Lung Transpl. 29, 914\u2013956 (2010).","journal-title":"J. Heart Lung Transpl."},{"key":"80790_CR7","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.healun.2015.04.001","volume":"34","author":"D Ansari","year":"2015","unstructured":"Ansari, D. et al. Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. J. Heart Lung Transpl. 34, 1283\u20131291 (2015).","journal-title":"J. Heart Lung Transpl."},{"key":"80790_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.healun.2017.07.016","volume":"36","author":"DC Chambers","year":"2017","unstructured":"Chambers, D. C. et al. The registry of the international society for heart and lung transplantation: Thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: Allograft ischemic time. J. Heart Lung Transpl. 36, 1047\u20131059 (2017).","journal-title":"J. Heart Lung Transpl."},{"key":"80790_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.athoracsur.2003.07.006","volume":"77","author":"XM Mueller","year":"2004","unstructured":"Mueller, X. M. Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants. Ann. Thorac. Surg. 77, 354\u2013362 (2004).","journal-title":"Ann. Thorac. Surg."},{"key":"80790_CR10","first-page":"329","volume":"15","author":"FW Smart","year":"1996","unstructured":"Smart, F. W. et al. Risk factors for early, cumulative, and fatal infections after heart transplantation: A multiinstitutional study. J. Heart Lung Transpl. 15, 329\u2013341 (1996).","journal-title":"J. Heart Lung Transpl."},{"key":"80790_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.healun.2007.06.004","volume":"26","author":"DO Taylor","year":"2007","unstructured":"Taylor, D. O. et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth official adult heart transplant report\u20132007. J. Heart Lung Transpl. 26, 769\u2013781 (2007).","journal-title":"J. Heart Lung Transpl."},{"key":"80790_CR12","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1056\/NEJMra064928","volume":"357","author":"JA Fishman","year":"2007","unstructured":"Fishman, J. A. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357, 2601\u20132614 (2007).","journal-title":"N. Engl. J. Med."},{"key":"80790_CR13","first-page":"21","volume":"1","author":"J Hahn","year":"1990","unstructured":"Hahn, J. et al. A survey on the cytomegalovirus antibodies in blood donors and the diseased. Korean J. Blood Transfus. 1, 21\u201334 (1990).","journal-title":"Korean J. Blood Transfus."},{"issue":"Suppl 7","key":"80790_CR14","doi-asserted-by":"publisher","first-page":"S701","DOI":"10.1093\/clinids\/12.Supplement_7.S701","volume":"12","author":"M Ho","year":"1990","unstructured":"Ho, M. Epidemiology of cytomegalovirus infections. Rev. Infect. Dis. 12(Suppl 7), S701-710 (1990).","journal-title":"Rev. Infect. Dis."},{"key":"80790_CR15","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/j.1600-6143.2010.03114.x","volume":"10","author":"A Asberg","year":"2010","unstructured":"Asberg, A. et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am. J. Transpl. 10, 1881\u20131888 (2010).","journal-title":"Am. J. Transpl."},{"key":"80790_CR16","doi-asserted-by":"crossref","unstructured":"Hoppe, L. et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients, in Transplantlantation Proceedings, Vol. 38 1922\u20131923 (Elsevier, 2006).","DOI":"10.1016\/j.transproceed.2006.06.075"},{"key":"80790_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","volume":"56","author":"AL Taylor","year":"2005","unstructured":"Taylor, A. L., Watson, C. J. & Bradley, J. A. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit. Rev. Oncol. Hematol. 56, 23\u201346 (2005).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"80790_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/088922203765551719","volume":"19","author":"M N\u00fa\u00f1ez","year":"2003","unstructured":"N\u00fa\u00f1ez, M. et al. Rate, causes, and clinical implications of presenting with low CD4+ cell counts in the era of highly active antiretroviral therapy. AIDS Res. Hum. Retrovir. 19, 363\u2013368 (2003).","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"80790_CR19","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1086\/644509","volume":"200","author":"L Couzi","year":"2009","unstructured":"Couzi, L. et al. Common features of \u03b3\u03b4 T cells and CD8+ \u03b1\u03b2 T cells responding to human cytomegalovirus infection in kidney transplant recipients. J. Infect. Dis. 200, 1415\u20131424 (2009).","journal-title":"J. Infect. Dis."},{"key":"80790_CR20","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/cid\/cis818","volume":"55","author":"A Egli","year":"2012","unstructured":"Egli, A., Humar, A. & Kumar, D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: A primer for the clinician. Clin. Infect. Dis. 55, 1678\u20131689 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"80790_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/tri.12321","volume":"27","author":"M Fern\u00e1ndez-Ruiz","year":"2014","unstructured":"Fern\u00e1ndez-Ruiz, M. et al. Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. Transpl. Int. 27, 674\u2013685 (2014).","journal-title":"Transpl. Int."},{"key":"80790_CR22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/TP.0b013e318239e90c","volume":"93","author":"SA Calarota","year":"2012","unstructured":"Calarota, S. A. et al. Kinetics of T-lymphocyte subsets and posttransplant opportunistic infections in heart and kidney transplant recipients. Transplantation 93, 112\u2013119 (2012).","journal-title":"Transplantation"},{"key":"80790_CR23","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/cid\/ciy295","volume":"67","author":"BJ Gardiner","year":"2018","unstructured":"Gardiner, B. J. et al. Absolute lymphocyte count: A Predictor of recurrent cytomegalovirus disease in solid organ transplant recipients. Clin. Infect. Dis. 67, 1395\u20131402 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"80790_CR24","first-page":"1497","volume":"20","author":"NE Nierenberg","year":"2014","unstructured":"Nierenberg, N. E. et al. Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation. Liver Transpl. 20, 1497\u20131507 (2014).","journal-title":"Liver Transpl."},{"key":"80790_CR25","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/lt.21833","volume":"15","author":"M Fern\u00e1ndez-Ruiz","year":"2009","unstructured":"Fern\u00e1ndez-Ruiz, M. et al. Pretransplant lymphocyte count predicts the incidence of infection during the first two years after liver transplantation. Liver Transpl. 15, 1209\u20131216 (2009).","journal-title":"Liver Transpl."},{"key":"80790_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ajt.12103","volume":"13","author":"RR Razonable","year":"2013","unstructured":"Razonable, R. R. & Humar, A. Cytomegalovirus in solid organ transplantation. Am. J. Transpl. 13, 93\u2013106 (2013).","journal-title":"Am. J. Transpl."},{"key":"80790_CR27","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11908-012-0292-2","volume":"14","author":"E Beam","year":"2012","unstructured":"Beam, E. & Razonable, R. R. Cytomegalovirus in solid organ transplantation: Epidemiology, prevention, and treatment. Curr. Infect. Dis. Rep. 14, 633\u2013641 (2012).","journal-title":"Curr. Infect. Dis. Rep."},{"key":"80790_CR28","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.healun.2005.03.019","volume":"24","author":"S Stewart","year":"2005","unstructured":"Stewart, S. et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transpl. 24, 1710\u20131720 (2005).","journal-title":"J. Heart Lung Transpl."},{"key":"80790_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3349\/ymj.2019.60.5.423","volume":"60","author":"JH Kim","year":"2019","unstructured":"Kim, J. H. et al. Association of newly developed right bundle branch block with graft rejection following heart transplantation. Yonsei Med. J. 60, 423\u2013428 (2019).","journal-title":"Yonsei Med. J."},{"key":"80790_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman, P. et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin. Infect. Dis. 64, 87\u201391 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"80790_CR31","doi-asserted-by":"publisher","first-page":"e0181590","DOI":"10.1371\/journal.pone.0181590","volume":"12","author":"KY Lee","year":"2017","unstructured":"Lee, K. Y. et al. Predictors of mortality in autoimmune disease patients with concurrent cytomegalovirus infections detected by quantitative real-time PCR. PLoS ONE 12, e0181590 (2017).","journal-title":"PLoS ONE"},{"key":"80790_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/cid\/ciw370","volume":"63","author":"JK Preiksaitis","year":"2016","unstructured":"Preiksaitis, J. K. et al. Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin. Infect. Dis. 63, 583\u2013589 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"80790_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jcv.2012.09.017","volume":"56","author":"C Martin-Gandul","year":"2013","unstructured":"Martin-Gandul, C. et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J. Clin. Virol. 56, 13\u201318 (2013).","journal-title":"J. Clin. Virol."},{"key":"80790_CR34","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","volume":"12","author":"SF Atabani","year":"2012","unstructured":"Atabani, S. F. et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am. J. Transpl. 12, 2457\u20132464 (2012).","journal-title":"Am. J. Transpl."},{"key":"80790_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jcv.2012.10.015","volume":"56","author":"M Boaretti","year":"2013","unstructured":"Boaretti, M. et al. Quantification of cytomegalovirus DNA by a fully automated real-time PCR for early diagnosis and monitoring of active viral infection in solid organ transplant recipients. J. Clin. Virol. 56, 124\u2013128 (2013).","journal-title":"J. Clin. Virol."},{"key":"80790_CR36","doi-asserted-by":"publisher","first-page":"e0163722","DOI":"10.1371\/journal.pone.0163722","volume":"11","author":"PD Griffiths","year":"2016","unstructured":"Griffiths, P. D. et al. Randomized controlled trials to define viral load thresholds for cytomegalovirus pre-emptive therapy. PLoS ONE 11, e0163722 (2016).","journal-title":"PLoS ONE"},{"key":"80790_CR37","doi-asserted-by":"publisher","first-page":"ofy230","DOI":"10.1093\/ofid\/ofy230","volume":"5","author":"A Meesing","year":"2018","unstructured":"Meesing, A. & Razonable, R. R. Absolute lymphocyte count thresholds: A simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation. Open Forum Infect. Dis. 5, ofy230 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"80790_CR38","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/TP.0000000000002396","volume":"103","author":"A Meesing","year":"2019","unstructured":"Meesing, A., Abraham, R. S. & Razonable, R. R. Clinical correlation of cytomegalovirus infection With CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients. Transplantation 103, 832\u2013838 (2019).","journal-title":"Transplantation"},{"key":"80790_CR39","first-page":"119","volume":"24","author":"C Branco","year":"2017","unstructured":"Branco, C., Prieto, D., Antunes, A. & Batista, M. Heart transplantation: Early results of two different regimes of immnunosuppression. Rev. Port. Cir. Cardiotorac. Vasc. 24, 119 (2017).","journal-title":"Rev. Port. Cir. Cardiotorac. Vasc."},{"key":"80790_CR40","doi-asserted-by":"crossref","unstructured":"Kittipibul, V. et al. Low-dose basiliximab induction therapy in heart transplantation. Clin Transplant 31 (2017).","DOI":"10.1111\/ctr.13132"},{"key":"80790_CR41","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/j.1600-6143.2009.02824.x","volume":"9","author":"RB Freeman Jr","year":"2009","unstructured":"Freeman, R. B. Jr. The \u201cindirect\u201d effects of cytomegalovirus infection. Am. J. Transpl. 9, 2453\u20132458 (2009).","journal-title":"Am. J. Transpl."},{"key":"80790_CR42","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1034\/j.1600-6143.2002.20907.x","volume":"2","author":"S Sagedal","year":"2002","unstructured":"Sagedal, S. et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am. J. Transpl. 2, 850\u2013856 (2002).","journal-title":"Am. J. Transpl."},{"key":"80790_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0002-9149(89)90535-3","volume":"64","author":"K McDonald","year":"1989","unstructured":"McDonald, K., Rector, T. S., Braulin, E. A., Kubo, S. H. & Olivari, M. T. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am. J. Cardiol. 64, 359\u2013362 (1989).","journal-title":"Am. J. Cardiol."},{"key":"80790_CR44","first-page":"213","volume":"32","author":"D Klimczak-Tomaniak","year":"2019","unstructured":"Klimczak-Tomaniak, D. et al. The association between cytomegalovirus infection and cardiac allograft vasculopathy in the era of antiviral valganciclovir prophylaxis. Transpl. Int. 32, 213\u2013213 (2019).","journal-title":"Transpl. Int."},{"key":"80790_CR45","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s12879-015-1321-1","volume":"15","author":"I Johansson","year":"2015","unstructured":"Johansson, I. et al. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients. BMC Infect. Dis. 15, 582 (2015).","journal-title":"BMC Infect. Dis."},{"key":"80790_CR46","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.healun.2015.03.015","volume":"34","author":"JF Delgado","year":"2015","unstructured":"Delgado, J. F. et al. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J. Heart Lung Transpl. 34, 1112\u20131119 (2015).","journal-title":"J. Heart Lung Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80790-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:19:30Z","timestamp":1670033970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80790-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80790"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80790-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1426"}}